Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Conference News TVT 2019

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Michael O'Riordan

June 19, 2019

News Conference News TVT 2019

Transcarotid Bests Aortic/Apical for Alternative TAVR Access: TVT Registry

Shelley Wood

June 17, 2019

News Conference News TVT 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Shelley Wood

June 16, 2017

Presentation TVT 2017

Spotlight Lecture: The SURTAVI LBCT: CoreValve vs Surgery in Intermediate-Risk Aortic Stenosis Patients

Presenter: David J. Cohen, Jeffrey J. Popma, Michael J. Reardon

June 16, 2017

Presentation TVT 2017

The Portico TAVR System: A Cool Case, New Technology, and Clinical Program Updates

Presenter: Martin B. Leon, Michael J. Reardon, Raj Makkar

June 16, 2017

Presentation TVT 2017

The ACURATE TAVR System: A Cool Case, New Technology, and Clinical Program Updates

Presenter: Martin B. Leon, Michael J. Reardon, Thomas Walther

June 16, 2017

Presentation TVT 2017

The LOTUS TAVR System: A Cool Case, New Technology (Including EDGE), and Clinical Program Updates

Presenter: Michael J. Reardon

June 16, 2017

Presentation TVT 2017

The REPRISE III LBCT: A Randomized Trial Comparing LOTUS vs Self-Expanding CoreValve in High-Risk Aortic Stenosis Patients

Presenter: Axel Linke, Jeffrey J. Popma, Michael J. Reardon

June 15, 2017

Presentation TVT 2014

Lessons Learned about Frailty and Comorbidities from the US CoreValve Trials

Presenter: Michael J. Reardon

June 07, 2014

Presentation TVT 2014

Direct Aortic is Clearly Superior to Transapical!

Presenter: Michael J. Reardon

June 07, 2014

Presentation TVT 2014

Direct Aortic TAVR: Indications, Optimal Technique, and Outcomes

Presenter: Michael J. Reardon

June 07, 2014

Presentation TVT 2014

Lotus - Status of the US Clinical Trial and Case Examples

Presenter: Ted E. Feldman, Michael J. Reardon

June 06, 2014

Presentation TVT 2014

The High-Risk Randomized Trial

Presenter: Michael J. Reardon

June 05, 2014

Advertisement

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Transcarotid Bests Aortic/Apical for Alternative TAVR Access: TVT Registry

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Spotlight Lecture: The SURTAVI LBCT: CoreValve vs Surgery in Intermediate-Risk Aortic Stenosis Patients

The Portico TAVR System: A Cool Case, New Technology, and Clinical Program Updates

The ACURATE TAVR System: A Cool Case, New Technology, and Clinical Program Updates

The LOTUS TAVR System: A Cool Case, New Technology (Including EDGE), and Clinical Program Updates

The REPRISE III LBCT: A Randomized Trial Comparing LOTUS vs Self-Expanding CoreValve in High-Risk Aortic Stenosis Patients

Lessons Learned about Frailty and Comorbidities from the US CoreValve Trials

Direct Aortic is Clearly Superior to Transapical!

Direct Aortic TAVR: Indications, Optimal Technique, and Outcomes

Lotus - Status of the US Clinical Trial and Case Examples

The High-Risk Randomized Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content